Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Director/PDMR Shareholding

1 Apr 2019 12:33

RNS Number : 6967U
Horizon Discovery Group plc
01 April 2019
 

Horizon Discovery Group plc

1 April 2019

 

 

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 1 April 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that on 29 March 2019 Mr Terry Pizzie and Mr Jayesh Pankhania, both Executive Directors of the Company, and Dr Ian Gilham and Mr Grahame Cook, both Non-Executive Directors of the Company, purchased ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").

Details of these purchases of Ordinary Shares, and each Director's resulting beneficial interest in the Company's issued share capital, are shown below:

Name of Director

Number of Ordinary Shares purchased

Average purchase price per share (pence)

Resulting number of Ordinary Shares held

Resulting number of Ordinary Shares held as a percentage of the Company's issued share capital

Mr Terry Pizzie

15,000

147.5

15,000

0.0100%

Mr Jayesh Pankhania*

13,533

147.7

13,533

0.0090%

Dr Ian Gilham*

13,549

147.6

70,037

0.0466%

Mr Grahame Cook**

20,150

149.0

62,400

0.0415%

 

*Purchased for ISA

**Purchased for Self-Invested Personal Pension fund

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Terry Pizzie

2

Reason for the notification

a)

Position/status

Chief Executive Officer - Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Average Price

No. of shares

£1.475

15,000

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

15,000

£1.475

£22,125

f)

Date of the transaction

29 March 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Jayesh Pankhania

2

Reason for the notification

a)

Position/status

Chief Financial Officer - Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Average Price

No. of shares

£1.476837

13,533

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

13,533

£1.476837

£19,986.04

f)

Date of the transaction

29 March 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ian Gilham

2

Reason for the notification

a)

Position/status

Non- Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Average Price

No. of shares

£1.47612

13,549

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

13,549

£1.47612

£19,999.95

f)

Date of the transaction

29 March 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Grahame Cook

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 Identification code

Ordinary shares of 1.0 pence each

 GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Average Price

No. of shares

£1.49

20,150

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

20,150

£1.49

£30,023.50

f)

Date of the transaction

29 March 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: +44 (0) 1223 655 580

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / James Black / Duncan Monteith

Tel: +44 (0) 207 260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFFLFBKZFLBBK
Date   Source Headline
8th Jul 20207:00 amRNSNotice of Trading Update & Capital Markets Webinar
26th Jun 20207:00 amRNSDirector/PDMR Shareholding
18th Jun 20201:00 pmRNSResult of AGM
18th Jun 20201:00 pmRNSDirector/PDMR Shareholding
5th Jun 20205:34 pmRNSHolding(s) in Company
4th Jun 202011:11 amRNSHoldings in Company
29th May 20207:00 amRNSDirector/PDMR Shareholding
22nd May 20207:00 amRNSAnnual Report and Notice of AGM
5th May 20205:46 pmRNSHolding(s) in Company
5th May 20201:34 pmRNSHolding(s) in Company
4th May 20201:58 pmRNSDirector/PDMR Shareholding
4th May 20207:00 amRNSDirector/PDMR Shareholding
1st May 20207:00 amRNSBoard Changes
29th Apr 202010:43 amRNSHolding(s) in Company
27th Apr 20207:00 amRNSFull Year Unaudited Results 2019
17th Apr 20203:56 pmRNSResults of Placing
17th Apr 202011:00 amRNSProposed Placing and COVID-19 update
3rd Apr 202011:35 amRNSHolding(s) in Company
2nd Apr 20204:40 pmRNSSecond Price Monitoring Extn
2nd Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 202010:56 amRNSHoldings in Company
27th Mar 20207:00 amRNSFull Year Results Deferral and COVID-19 Update
25th Mar 202011:20 amRNSHolding(s) in Company
19th Mar 20204:43 pmRNSSecond Price Monitoring Extn
19th Mar 20204:39 pmRNSPrice Monitoring Extension
17th Mar 202012:03 pmRNSPrice Monitoring Extension
27th Feb 202010:38 amRNSDirector/PDMR Shareholding
26th Feb 20207:00 amRNSPresentation Cowen Annual Health Care Conference
17th Feb 20207:00 amRNSTotal Voting Rights
14th Feb 20202:46 pmRNSHolding(s) in Company
4th Feb 20207:00 amRNSConfidential submission of Form F-1 to SEC
4th Feb 20207:00 amRNSTrading Update
27th Jan 20201:51 pmRNSBlock Listing Six Monthly Return
14th Jan 20207:00 amRNSUpdate on Base Editing Technology License
18th Dec 20197:00 amRNSPresentation at J.P. Morgan Healthcare Conference
16th Dec 201912:07 pmRNSSecond Price Monitoring Extn
16th Dec 201912:02 pmRNSPrice Monitoring Extension
13th Dec 20197:00 amRNSCollaboration with Mammoth Biosciences
4th Dec 201912:08 pmRNSSecond Price Monitoring Extn
4th Dec 201912:02 pmRNSPrice Monitoring Extension
4th Dec 20197:00 amRNSCompletion of Divestment of In Vivo Business Unit
8th Nov 20197:00 amRNSDivestment of In Vivo Business Unit
22nd Oct 20193:22 pmRNSAdditional Block Listing and Total Voting Rights
4th Oct 201912:07 pmRNSSecond Price Monitoring Extn
4th Oct 201912:02 pmRNSPrice Monitoring Extension
19th Sep 20193:30 pmRNSHolding(s) in Company
16th Sep 20197:00 amRNSHalf-year Report
12th Aug 201912:07 pmRNSSecond Price Monitoring Extn
12th Aug 201912:02 pmRNSPrice Monitoring Extension
26th Jul 20197:00 amRNSBlock Listing Six Monthly Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.